Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

被引：0
|
作者：
Shukui Qin
Jin Li
Haijun Zhong
Chuan Jin
Lili Chen
Xianglin Yuan
Qingxia Fan
Kehe Chen
Peiguo Cao
Jianjun Xiao
Da Jiang
Tao Zhang
Hongyu Zhang
Xicheng Wang
Wei Wang
Lin Han
Qingyu Wang
Jun Zhu
机构：
[1] Eastern Theater General Hospital of PLA China,Department of Oncology, Qinhuai Medical Area
[2] Tongji University Shanghai East Hospital,Department of Oncology
[3] Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Department of Abdominal Oncology
[4] Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Department of Oncology
[5] Taizhou First People’s Hospital,Department of Hematology and Oncology
[6] Tongji Hospital,Department of Oncology
[7] Huazhong University of Science and Technology,Department of Oncology
[8] The First Affiliated Hospital of Zhengzhou University,Department of Oncology
[9] The People’s Hospital of Guangxi Zhuang Autonomous Region,Department of Oncology
[10] The Third Xiangya Hospital of Central South University,Chemotherapeutic Department
[11] Zhongshan City People’s Hospital,Department of Oncology
[12] The Fourth Hospital of Hebei Medical University,Department of Oncology
[13] The First Affiliated Hospital of Chongqing Medical University,Cancer Center
[14] The Fifth Affiliated Hospital Sun Yat-sen University,Department of Oncology
[15] The First Affiliated Hospital of Guangdong Pharmaceutical University,Department of Gastrointestinal Oncology
[16] The First People’s Hospital of Foshan,undefined
[17] Shanghai Henlius Biotech,undefined
[18] Inc.,undefined
来源：
British Journal of Cancer | 2022年 / 127卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2249 / 2249
相关论文
共 50 条
  • [41] Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial
    Wu, Xiaohua
    Ji, Jiafu
    Lou, Hanmei
    Li, Yunxia
    Feng, Mei
    Xu, Nong
    Li, Yuzhi
    Wang, Jing
    Huang, Yi
    Lou, Ge
    An, Ruifang
    Li, Changzheng
    Zhou, Qi
    Huang, Xin
    Zhao, Enfeng
    Liu, Tianshu
    Fan, Qingxia
    Li, Guiling
    Li, Baiyong
    Xia, Yu
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S47 - S48
  • [42] Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study
    Yu, Jie-Hai
    Xiao, Bin-Yi
    Li, Dan-Dan
    Jiang, Wu
    Ding, Ya
    Wu, Xiao-Jun
    Zhang, Rong-Xin
    Lin, Jun-Zhong
    Wang, Wei
    Han, Kai
    Kong, Ling-Heng
    Zhang, Xin-Ke
    Chen, Bi-Yun
    Mei, Wei-Jian
    Pan, Zhi-Zhong
    Tang, Jing-Hua
    Zhang, Xiao-Shi
    Ding, Pei-Rong
    LANCET ONCOLOGY, 2024, 25 (07): : 843 - 852
  • [43] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Makker, Vicky
    Rasco, Drew
    Vogelzang, Nicholas J.
    Brose, Marcia S.
    Cohn, Allen L.
    Mier, James
    Di Simone, Christopher
    Hyman, David M.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Schmidt, Emmett V.
    Guo, Matthew
    Sachdev, Pallavi
    Shumaker, Robert
    Aghajanian, Carol
    Taylor, Matthew
    LANCET ONCOLOGY, 2019, 20 (05): : 711 - 718
  • [44] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [45] Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
    Negrier, Sylvie
    Rioux-Leclercq, Nathalie
    Ferlay, Celine
    Gross-Goupil, Marine
    Gravis, Gwenaelle
    Geoffrois, Lionel
    Chevreau, Christine
    Boyle, Helen
    Rolland, Frederic
    Blanc, Ellen
    Ravaud, Alain
    Dermeche, Slimane
    Flechon, Aude
    Albiges, Laurence
    Perol, David
    Escudier, Bernard
    EUROPEAN JOURNAL OF CANCER, 2020, 129 : 107 - 116
  • [46] Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
    Liu, Rui
    Ji, Zhi
    Wang, Xia
    Zhu, Lila
    Xin, Jiaqi
    Ma, Lijun
    Zhang, Jiayu
    Ge, Shaohua
    Zhang, Le
    Yang, Yuchong
    Ning, Tao
    Bai, Ming
    Duan, Jingjing
    Wang, Feixue
    Sun, Yansha
    Li, Hongli
    Deng, Ting
    Ba, Yi
    Hao, Jihui
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [47] A PHASE 1 STUDY OF SERPLULIMAB (A NOVEL ANTI-PD-1 ANTIBODY) IN COMBINATION WITH HLX04 (AN ANTI-VEGF ANTIBODY) IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Guo, Y.
    Li, J.
    Li, Q.
    Xue, J.
    Xue, L.
    Ge, X.
    Lin, F.
    Zhao, W.
    Tang, W.
    Peng, D.
    Wang, Q.
    Zhu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S29 - S30
  • [48] Anti-PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.
    Wang, Jing
    Li, Siqi
    Jiang, Hao
    Chang, Ying-Jun
    Zhao, Xiao-Su
    Jia, Jin-Song
    Zhu, Xiao-Lu
    Gong, Li-Zhong
    Liu, Xiao-Hong
    Yu, Wen-Jing
    Huang, Xiao-Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
    Cousin, Sophie
    Cantarel, Coralie
    Guegan, Jean-Philippe
    Mazard, Thibault
    Gomez-Roca, Carlos
    Metges, Jean-Philippe
    Bellera, Carine
    Adenis, Antoine
    Korakis, Iphigenie
    Poureau, Pierre-Guillaume
    Bourcier, Kevin
    Toulmonde, Maud
    Kind, Michele
    Rey, Christophe
    Auzanneau, Celine
    Bessede, Alban
    Soubeyran, Isabelle
    Italiano, Antoine
    EUROPEAN JOURNAL OF CANCER, 2022, 162 : 161 - 169
  • [50] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
    Lan, Chunyan
    Shen, Jingxian
    Wang, Yin
    Li, Jundong
    Liu, Zhimin
    He, Mian
    Cao, Xinping
    Ling, Jiayu
    Huang, Jiaming
    Zheng, Min
    Zou, Guorong
    Yan, Haowen
    Liu, Qing
    Yang, Fan
    Wei, Wei
    Deng, Yanhong
    Xiong, Ying
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
12345